NPS Pharmaceuticals, Inc. (NPSP) Posts Wider than Expected Q4 Loss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/13/2026
- Nasdaq ends down as chipmakers fall and bank earnings roll in
- Oil prices settle mixed, focus on US-Russia diesel deal, Saudi Yemen attacks
- JPMorgan shares edge lower after third-quarter FICC revenue miss
- Fed’s Waller says US bond yield rise driven by growth, not inflation
- Wells Fargo beats profit estimates despite revenue miss
Tweet
Share
E-mailGet Alerts NPSP Hot Sheet
Price: $45.97 --0%
Financial Fact:
Research and development: 24.53M
Today's EPS Names:
SODI, PGR, OMID, More
Financial Fact:
Research and development: 24.53M
Today's EPS Names:
SODI, PGR, OMID, More
Join SI Premium – FREE
NPS Pharmaceuticals, Inc. (NASDAQ: NPSP) reported Q4 EPS of ($0.10), $0.01 worse than the analyst estimate of ($0.09). Revenue for the quarter came in at $26.3 million versus the consensus estimate of $26.17 million.
For earnings history and earnings-related data on NPS Pharmaceuticals, Inc. (NPSP) click here.
For earnings history and earnings-related data on NPS Pharmaceuticals, Inc. (NPSP) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman’s CEO Solomon says to watch political volatility around data centers
- S&P upgrades Kioxia to BBB on strong AI-driven growth and upbeat outlook
- Brookdale buys 17 communities, agrees to acquire 30 more from Welltower
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
